Seguir
Lisa A. Carey, MD, FASCO
Lisa A. Carey, MD, FASCO
Dirección de correo verificada de med.unc.edu
Título
Citado por
Citado por
Año
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
LA Carey, CM Perou, CA Livasy, LG Dressler, D Cowan, K Conway, ...
Jama 295 (21), 2492-2502, 2006
46752006
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
LA Carey, EC Dees, L Sawyer, L Gatti, DT Moore, F Collichio, DW Ollila, ...
Clinical cancer research 13 (8), 2329-2334, 2007
25892007
The molecular portraits of breast tumors are conserved across microarray platforms
Z Hu, C Fan, DS Oh, JS Marron, X He, BF Qaqish, C Livasy, LA Carey, ...
BMC genomics 7 (1), 1-12, 2006
17702006
Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
JD Brenton, LA Carey, AA Ahmed, C Caldas
Journal of clinical oncology 23 (29), 7350-7360, 2005
12322005
Epidemiology of basal-like breast cancer
RC Millikan, B Newman, CK Tse, PG Moorman, K Conway, LV Smith, ...
Breast cancer research and treatment 109 (1), 123-139, 2008
11202008
4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4)
F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ...
Annals of Oncology 29 (8), 1634-1657, 2018
10182018
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
10052017
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete …
WM Sikov, DA Berry, CM Perou, B Singh, CT Cirrincione, SM Tolaney, ...
Journal of clinical oncology 33 (1), 13, 2015
9182015
Triple-negative breast cancer: disease entity or title of convenience?
L Carey, E Winer, G Viale, D Cameron, L Gianni
Nature reviews Clinical oncology 7 (12), 683-692, 2010
8972010
3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3)
F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ...
The Breast 31, 244-259, 2017
7912017
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer
CK Anders, LA Carey
Clinical breast cancer 9, S73-S81, 2009
7842009
Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals
A Flanagin, LA Carey, PB Fontanarosa, SG Phillips, BP Pace, ...
Jama 280 (3), 222-224, 1998
7131998
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ...
New England Journal of Medicine 382 (7), 597-609, 2020
7122020
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast CancerBicalutamide in AR (+) ER/PgR (−) Metastatic …
A Gucalp, S Tolaney, SJ Isakoff, JN Ingle, MC Liu, LA Carey, K Blackwell, ...
Clinical cancer research 19 (19), 5505-5512, 2013
6982013
Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3
DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ...
Journal of Clinical Oncology 36 (24), 2465-2472, 2018
6872018
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ...
New England Journal of Medicine 372 (2), 134-141, 2015
6832015
Molecular characterization of basal‐like and non‐basal‐like triple‐negative breast cancer
A Prat, B Adamo, MCU Cheang, CK Anders, LA Carey, CM Perou
The oncologist 18 (2), 123-133, 2013
6312013
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ...
Annals of Oncology 31 (12), 1623-1649, 2020
5682020
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
LA Carey, HS Rugo, PK Marcom, EL Mayer, FJ Esteva, CX Ma, MC Liu, ...
Journal of clinical oncology 30 (21), 2615, 2012
5582012
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer
M Kaufmann, G Von Minckwitz, EP Mamounas, D Cameron, LA Carey, ...
Annals of surgical oncology 19 (5), 1508-1516, 2012
5122012
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20